BioTech Nation ... with Dr. Moira Gunn

Beyond Pills and Shots... Sean Ainsworth, CEO, Immusoft

Moira Gunn — Wed, 16 Apr 2025 08:00:00 -0700

This week on BioTech Nation, Sean Ainsworth, CEO of ImmuSoft, explains how modifying the body’s own B cells to produce therapeutic proteins could revolutionize drug delivery. From improving treatment for rare diseases like Hurler syndrome to potentially replacing injections for autoimmune and metabolic conditions, this new approach opens the door to long-term, patient-specific solutions.

Breaking Barriers in Brain Cancer... Dr. Thomas Chen, Founder and CEO, NeOnc Technologies

Moira Gunn — Wed, 09 Apr 2025 08:00:00 -0700

This week on BioTech Nation, Dr. Thomas Chen, Director of Neuro-Oncology at USC and Founder of NeOnc Technologies, shares treating glioblastoma by delivering a drug directly to the brain through nasal inhalation changes the drug delivery game, bypassing the blood-brain barrier. This technique is achieving results in clinical trials.

The Future of Synthetic Biology... Dr. John Cumbers, Founder & CEO, SynBioBeta

Moira Gunn — Wed, 02 Apr 2025 08:00:00 -0700

This week on BioTech Nation, I speak with Dr. John Cumbers, founder and CEO of SynBioBeta, the annual synthetic biology conference. We discuss how biology, AI, and technology are transforming industries, covering tracks on human health, planetary health, and hyperscale biology. SynBioBeta 2025 will take place in San Jose, CA, from May 5 to 8.

Reimagining Bone Marrow Transplants... Kevin Caldwell, Co-Founder & CEO, Ossium Health

Moira Gunn — Wed, 26 Mar 2025 08:00:00 -0700

This week on BioTech Nation, Ossium Health co-founder and CEO Kevin Caldwell shares how their breakthrough approach is changing bone marrow transplants. By cryobanking marrow from organ donors, Ossium is reducing wait times, improving access, and preparing for future emergencies. With support from BARDA and promising clinical trial results, this new system could help thousands more receive lifesaving transplants—right when they need them.

When Your Immune System Attacks You... Prof. Dr. Niels Riedemann, Co-Founder & CEO, Inflarx

Moira Gunn — Wed, 19 Mar 2025 08:00:00 -0700

This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies.

Designing Healthcare for People... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 12 Mar 2025 08:00:00 -0700

This week on BioTech Nation, Dr. Daniel Kraft explores how smarter design can make healthcare easier, less stressful, and more effective. From hospitals built for patient comfort to medical apps that adapt to your needs, the way we experience healthcare is evolving. Learn how design thinking and empathy are shaping the future of medicine.

Why One Drug Isn't Always Enough... Rich Daly, President & CEO, Catalyst Pharmaceuticals

Moira Gunn — Wed, 05 Mar 2025 08:00:00 -0800

This week on BioTech Nation, Catalyst Pharmaceuticals CEO Rich Daly discusses the complexities of treating epilepsy and rare diseases. From the challenges of polypharmacy—where patients need multiple drugs to manage a single condition—to the hurdles of diagnosing and treating ultra-rare diseases.

A Second Chance for an ALS Drug... Dr. Ari Azhir, Founder & CEO, Neuvivo

Moira Gunn — Wed, 26 Feb 2025 08:00:00 -0800

This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.

The Mystery of "Dark" Proteins... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Thu, 20 Feb 2025 08:00:00 -0800

This week on BioTech Nation, Dr. Daniel Kraft explores the discovery of "dark" proteins, thousands of previously unknown proteins in the human body. Scientists believe these hidden proteins could be the key to detecting diseases earlier and developing new treatments.

9 Million Samples: A New Era of Medicine... Dr. Lincoln Nadauld, President & CEO, Culmination Bio

Moira Gunn — Wed, 12 Feb 2025 08:00:00 -0800

This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.

Mobility: The New Vital Sign….Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 05 Feb 2025 08:00:00 -0800

This week on Biotech Nation, Dr. Daniel Kraft discusses why mobility is emerging as a key indicator of health, just like heart rate or blood pressure. From wearable tech that tracks your gait to AI-powered exoskeletons and brain-computer interfaces, new innovations are transforming how we measure and maintain movement.

Reprogramming the Future... Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian Biotechnology

Moira Gunn — Wed, 29 Jan 2025 08:00:00 -0800

This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.

One Drug, Many Diseases??? Dr. David Fajgenbaum, UPenn School of Medicine Professor and President of Every Cure

Moira Gunn — Wed, 22 Jan 2025 08:00:00 -0800

Not just seeking treatment for every disease, but making sure the treatments we have already developed are being used in every possible way. I speak with Dr. David Fajgenbaum (Fay-gen-baum), a Professor of Translational Medicine and Human Genetics at the University of Pennsylvania School of Medicine, and President of Every Cure.

A Daily Pill to Fight Autoimmune Diseases…Ben Zimmer, CEO of Priovant Therapeutics

Moira Gunn — Wed, 15 Jan 2025 08:00:00 -0800

This week on Biotech Nation, Priovant Therapeutics CEO Ben Zimmer shares how their once-a-day pill could transform the treatment of severe autoimmune diseases like dermatomyositis and non-infectious uveitis. With phase 3 trials in progress, Priovant is offering hope to patients with few modern treatment options.

Fighting Inflammation, and Alzheimer's??? Dr. David Bearss, President & CEO Halia Therapeutics

Moira Gunn — Wed, 08 Jan 2025 08:00:00 -0800

In this week's episode of BioTech Nation, Dr. David Bearss, President and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered protein complex critical in regulating inflammatory responses and its potential in treating chronic diseases like myelodysplastic syndrome and Alzheimer's. Dr. Bearss shares insights into Halia's groundbreaking approach and his relentless pursuit of medical breakthroughs.

Alcohol-Associated Hepatitis Treatment on the Horizon!!! Dr. Jim Brown, CEO of DURECT

Moira Gunn — Wed, 01 Jan 2025 08:00:00 -0800

Dr. Jim Brown from DURECT talks about their clinical trials for Alcohol-Associated Hepatitis, a condition for which there is no approved treatment.

Data for Good!!!... Sir Rory Collins, Oxford Professor and Principal Investigator, UK Biobank

Moira Gunn — Wed, 25 Dec 2024 08:00:00 -0800

Sir Rory Collins is a Professor of Medicine and Epidemiology at the University of Oxford and the Principal Investigator of the UK Biobank. With data from half a million people, it has served 30,000 scientists around the world, giving special support to young researchers and scientists in emergent countries.

Building Technology and Solving Problems!!! Dave Pacitti, President & Head of the Americas, Siemens Healthineers

Moira Gunn — Wed, 18 Dec 2024 08:00:00 -0800

When is a medical technology company more than a medical technology company? We’ll hear all about it when I speak with Dave Pacitti, the President and Head of the Americas at Siemens Healthineers. They’re out to solve problems bigger than the products they are known for.

Antidepressants Should Have Diagnostics??? Dr. Amit Etkin, Founder & CEO, Alto Neuroscience

Moira Gunn — Wed, 11 Dec 2024 08:00:00 -0800

Major Depressive Disorder. Serious Depression. PTSD. Alto Neuroscience CEO, Dr. Amit Etkin talks about developing new and innovative drugs tied directly to each patient’s underlying biology. For every drug, there is a test...

Can AI Discover Drugs Better Than Humans?? Dr. Vimal Mehta, Co-Founder & CEO BioXcel

Moira Gunn — Wed, 04 Dec 2024 08:00:00 -0800

Discover how their AI technology is revolutionizing drug discovery with Dr. Vimal Mehta, Co-Founder and CEO BioXcel and how this is leading to the approval of their first drug for agitation in bipolar I and II and schizophrenia, and paving the way for new treatments.

Food IS Medicine... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 27 Nov 2024 08:00:00 -0800

This week on Biotech Nation, Tech Nation Health Chief Correspondent, Dr. Daniel Kraft, talks about “food as medicine" and how eating real, minimally processed food can prevent chronic illnesses like diabetes and heart disease, starting with kids and school lunches. Programs like Eat Real and the federal Food is Medicine initiative are working to improve diets and health nationwide.

Rewiring the Brain... Dr. Peter Vanderklish, Chief Scientific Officer, Spinogenix

Moira Gunn — Wed, 20 Nov 2024 08:00:00 -0800

This week on BioTech Nation, Dr. Peter Vanderklish, Chief Scientific Officer at Spinogenix discusses their clinical trials focused on regenerating synapses to repair brain connections and offer hope for conditions like Alzheimer's, ALS, schizophrenia and depression. Phase 2 trials are underway. Check their website for patient recruitment information.

Sepsis: First-Time-Ever Test... Dr. Rollie Carlson, CEO Immunexpress

Moira Gunn — Wed, 13 Nov 2024 08:00:00 -0800

This week on BioTech Nation, Dr. Rollie Carlson, CEO of Immunexpress, talks about Sepsis—a deadly condition responsible for 1 in 5 deaths worldwide. Dr. Carlson talks about the FDA-cleared SeptiCyte test, a new tool that can quickly identify Sepsis within an hour, helping doctors treat it faster and avoid unnecessary antibiotics or even death.

CRISPR Dilemma... Dr. Eben Kirksey, Anthropologist & Author, “The Mutant Project: Inside the Global Race to Genetically Modify Humans”

Moira Gunn — Wed, 06 Nov 2024 10:14:40 -0800

This week on BioTech Nation, we talk with Dr. Eben Kirksey about the ethical issues behind CRISPR, the gene-editing tool that made headlines with the birth of the first “CRISPR babies” in China. Dr. Kirksey shares his experiences investigating this controversial experiment and highlights the deeper questions it raises. He stresses the importance of public dialogue, urging us to consider carefully who benefits from such powerful technologies as we shape the future of gene editing.

AI & Better Health...Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 30 Oct 2024 08:00:00 -0700

This week on BioTech Nation, Dr. Daniel Kraft talks about how AI can personalize health advice using data from devices like your smartwatch. He explains how this technology can help people make better choices to stay healthy and avoid major illnesses. Dr. Kraft envisions AI as a personal health coach, offering real-time tips and reminders tailored to each person's needs.

A Smarter Path to Curing Diseases… Dr. Avak Kahvejian Founding CEO, Cellarity

Moira Gunn — Thu, 24 Oct 2024 08:00:00 -0700

Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.

Replacing Cells, Restoring Sight…Brian Culley, CEO, Lineage Cell Therapeutics

Moira Gunn — Wed, 16 Oct 2024 08:00:00 -0700

Brian Culley, CEO of Lineage Cell Therapeutics, talks about a new approach to treating diseases called whole cell replacement therapy - which replaces damaged cells with new ones. Lineage is focusing this new therapy on dry age-related macular degeneration (AMD), a leading cause of blindness, through their collaboration with Genentech..

Multimodal Health??? Dr. Daniel Kraft, Tech Nation Health, Chief Correspondent

Moira Gunn — Wed, 09 Oct 2024 08:00:00 -0700

Dr. Daniel Kraft, Tech Nation Health Chief Correspondent introduces "multimodal medicine", combining data like proteomics, wearables, and imaging for early disease detection. He stresses the importance of both advanced diagnostics and listening to patients' stories for effective healthcare.

15 Billion Vaccines Doses: COVID & the Patent Dilemma... Dr. Antony Taubman, Former Director of the Intellectual Property Division at the World Trade Organization

Moira Gunn — Wed, 02 Oct 2024 12:00:00 -0700

Dr. Antony Taubman, the former Director of the Intellectual Property Division at the World Trade Organization, discusses the challenges faced during the COVID-19 pandemic, including the rapid development and distribution of 15 billion doses of Covid vaccines, and how international intellectual property rules influenced these efforts.

From Illness to Wellness - Can Science Tell Us How Healthy We Really Are (Part II)?? Dr. Leroy Hood and Dr. Nathan Price

Moira Gunn — Wed, 25 Sep 2024 08:00:00 -0700

Part II - We continue our discussion with Dr. Leroy Hood and Dr. Nathan Price about the subject of their book "The Age of Scientific Wellness", delving into the role of artificial intelligence in healthcare and the ability to mine deep data to deliver hyper-personalized recommendations at a scale never before possible.

From Illness to Wellness - Can Science Tell Us How Healthy We Really Are (Part I)?? Dr. Leroy Hood and Dr. Nathan Price

Moira Gunn — Wed, 18 Sep 2024 08:00:00 -0700

Dr. Leroy Hood and Dr. Nathan Price delve into the subject of their book "The Age of Scientific Wellness", which highlights the advancements in science that enable the prediction and personalization of healthcare based on an individual's wellness level, and the potential advantages of early diagnosis and treatment of illnesses

One Pill to Stop Many Cancers??? Dr. Michael Weickert, CEO, Pacylex Pharmaceuticals

Moira Gunn — Wed, 11 Sep 2024 08:00:00 -0700

Dr. Michael Weickert, CEO of Pacylex Pharmaceuticals, about their once-daily pill in trials now for cancer treatment - it’s already showing early indicators of success in stopping cancer growth in not just one, but a number of cancers.

Engineering the Future of Vaccines... Dr. Robert Coleman, CEO, Codagenix

Moira Gunn — Wed, 04 Sep 2024 08:00:00 -0700

Dr. Robert Coleman, CEO of Codagenix, discusses their innovative approach to virus engineering, which includes developing a nasally-delivered COVID-19 vaccine that targets multiple virus proteins for broader protection. Codagenix's "rational virus design" method creates genetically stable vaccines and therapeutics, reducing the risk of harmful mutations. Their work also extends to vaccines for other diseases and viral-based cancer treatments, with the potential to significantly advance global health.

Did That Change To My Prescription Work??? -- Dr. Kal Patel, CEO, BrightInsight

Moira Gunn — Wed, 28 Aug 2024 08:00:00 -0700

Continuous monitoring ... when we want it, when we don’t, should we share it? Or not. Or perhaps just part of it. Dr. Kal Patel, the Co-Founder and CEO of BrightInsight talks about this brave new frontier.

Can the Mapping of Human Biology Lead to Better Drugs? Dr. Chris Gibson, Co-Founder & CEO Recursion Pharmaceuticals

Moira Gunn — Wed, 21 Aug 2024 08:00:00 -0700

Dr. Chris Gibson, the co-founder and CEO of Recursion Pharmaceuticals in Salt Lake City. We talk about their efforts to map ALL of human biology, and how this mapping will lead to better drugs.

One Company, Two Different Drugs - It's All About Glucose - Too Much and Too Little! Nevan Charles Elam, Founder & CEO, Rezolute

Moira Gunn — Wed, 14 Aug 2024 08:00:00 -0700

Glucose is essential for life. And the insulin we produce is designed to leave just the right of amount in our bodies for healthy functioning. Thus, when we underproduce insulin - or we overproduce it - the results can be devastating. Nevan Charles Elam, Founder and CEO of Rezolute, tells us about their work to treat the “diabetic eye condition”, DME, and a pediatric condition called Congenital hyperinsulinism.

A Vaccine for Breast Cancer??? Dr. Amit Kumar, President & CEO, Anixa Biosciences

Moira Gunn — Thu, 08 Aug 2024 10:18:49 -0700

This week on BioTech Nation, Dr. Amit Kumar, President and CEO of Anixa Biosciences, talks about their work on a breast cancer vaccine which targets a protein thought only to be expressed during breastfeeding. Building on research by the Cleveland Clinic, Dr. Kumar describes ongoing human clinical trials and their potential for women with BRCA mutations.

Are Your Genes Failing You??? Dr. Noah Davidsohn, Co-Founder & CSO Rejuvenate Bio

Moira Gunn — Wed, 31 Jul 2024 08:00:00 -0700

This week on Biotech Nation, Dr. Noah Davidsohn, Co-Founder and Chief Scientific Officer of Rejuvenate Bio. The discussion centers around the regulation of protein expression and its implications for aging and health. Dr. Davidsohn explains how aging disrupts the balance of protein production, leading to various diseases. Rejuvenate Bio's gene therapies aim to restore this balance by targeting specific genes.

Living Longer??? Dr. Peter Diamandis, XPrize Founder and Author, "Longevity"

Moira Gunn — Wed, 24 Jul 2024 08:00:00 -0700

This week of BioTech Nation, Dr. Peter Diamandis about his new book, "Longevity: Your Practical Playbook on Sleep, Diet, Exercise, Mindset, Medications, and Not Dying from Something Stupid". We explore his lifelong interest in extending human health span and discuss practical steps for a healthier, longer life, including sleep, diet, exercise, and mindset. Dr. Diamandis introduces the "longevity escape velocity" concept and the HealthSpan XPRIZE, which aims to reverse aging's functional losses.

Psychedelics... Prodrugs... What else? Dr. Sam Clark, CEO of Terran Biosciences

Moira Gunn — Wed, 17 Jul 2024 08:00:00 -0700

This week on BioTech Nation, Dr. Sam Clark, CEO of Terran Biosciences, discusses prodrugs—modified drugs that improve absorption and efficacy. Also, Terran Biosciences is developing non-hallucinogenic psychedelics by blocking the serotonin 2A receptor and manufacturing psychedelics like LSD and psilocybin for research. Dr. Clark highlights Terran's innovative, tech-inspired approach to rapidly develop affordable medications.

A Dual Approach to Combatting Hepatitis... Dr. Marianne De Backer, CEO at Vir Biotechnology

Moira Gunn — Wed, 10 Jul 2024 08:00:00 -0700

This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans.

Solving Genetic Diseases??? Dr. Neil Kumar, Founder & CEO, BridgeBio Pharma

Moira Gunn — Wed, 03 Jul 2024 08:00:00 -0700

This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of multiple specialized companies under a centralized infrastructure to efficiently tackle various genetic diseases. This model allows for focused expertise on individual conditions while sharing common resources. Dr. Kumar highlights the company's commitment to using diverse therapeutic modalities, such as small molecules and gene therapies, to develop treatments that address the underlying causes of these diseases.

The Next Ozempic or Wegovy... But Without the Injection??? Dr. Steffen-Sebastian Bolz, CSO, Aphaia Pharma

Moira Gunn — Wed, 26 Jun 2024 09:00:06 -0700

What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2.

FDA Approval! A New Model for BioPharma... Dr. Sam Blackman, Founder & Head of Research and Development, Day One Biopharmaceuticals

Moira Gunn — Wed, 26 Jun 2024 08:53:45 -0700

This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. He talks about their innovative approach to starting a biopharma company and how it led to a newly FDA approved drug that treats the most common form of brain cancer in children

Everybody Has a Thyroid... What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma

Moira Gunn — Wed, 19 Jun 2024 08:00:00 -0700

This week we have a best of rerun with Dr. Mark Sumeray from Amolyt Pharma. Dr. Sumeray talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

Wearable Wonders! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 12 Jun 2024 08:00:00 -0700

This week Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, discusses advanced health tech. Dr. Kraft highlights his use of wearables like the Apple Watch, Oura ring, and non-invasive blood pressure monitors. He also introduces "otherables," which track health without being worn, using devices like cameras and modified WiFi. These technologies enable continuous health monitoring and personalized care.

Robo-Docs & VR Surgery??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 29 May 2024 09:00:00 -0700

This week on BioTech Nation, Dr. Moira Gunn and Dr. Daniel Kraft discuss how robotics, AI, and virtual reality are transforming surgery. These technologies make procedures less invasive and improve training and outcomes worldwide. Future advancements may include tiny robots performing internal procedures. Security is crucial to prevent hacking of medical devices.

No More Transfusions!!! Dr. John Scarlett, President and CEO of Geron Corporation

Moira Gunn — Wed, 22 May 2024 08:00:00 -0700

Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval.

Closing the Innovation Gap!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 15 May 2024 08:00:00 -0700

Dr. Daniel Kraft, Tech Nation Health Chief Correspondent discusses the gap between medical innovation and its adoption into standard practice. He highlights that it typically takes 17 years for a medical discovery to become common practice, but big data and AI could accelerate this. He emphasizes the importance of sharing medical data and initiatives like Stuff That Works Health and EveryCure.

The Virtual Cell??? Dr. Steve Quake, Head of Science at Chan Zuckerberg Initiative

Moira Gunn — Wed, 08 May 2024 08:36:00 -0700

This week, Dr. Steve Quake from the Chan Zuckerberg Initiative about their goal to tackle all human diseases in the next century. We discuss CZI's innovative approach, including building Biohubs and funding collaborative research. Dr. Quake explains the importance of something called The Virtual Cell project, aiming to use AI to model every human cell. We also address ethical concerns about AI in bioweapons research and the need for regulatory measures.

How Can Sound Deliver Drugs??? Dr. Neal Kassell, Founder & Chair of Focused Ultrasound Foundation

Moira Gunn — Wed, 01 May 2024 08:00:00 -0700

This week on Biotech Nation, I speak with Dr. Neal Kassell about focused ultrasound technology. We discuss its noninvasive approach, its diverse applications in treating various medical conditions, and its potential to revolutionize treatments for diseases like Alzheimer's, Parkinson's, and cancer. Dr. Kassell also shares insights into ongoing clinical trials and the rapid growth of focused ultrasound as a global standard of care.

70% of Breast Cancers and a Link to Prostate Cancer... Dr. Sean Bohen, President & CEO, Olema Oncology

Moira Gunn — Wed, 24 Apr 2024 08:00:00 -0700

This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments.

Tiny RNAs, Big Cures!!! Dr. Sanjay Shukla, President and CEO, ATyr (ah-tire) Pharma

Moira Gunn — Wed, 17 Apr 2024 09:57:00 -0700

This week - Dr. Sanjay Shukla, CEO of Atyr Pharma, discusses the revolutionary potential of mRNA technology in creating new medicines. They explore Atyr's pioneering approach to leveraging tRNA fragments for treating pulmonary sarcoidosis and other organ-specific conditions, aiming to improve patient outcomes while minimizing reliance on conventional therapies like steroids.

How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics

Moira Gunn — Wed, 10 Apr 2024 08:00:00 -0700

Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.

Cancer Vaccines??? Dr. Chris Pirie, Co-Founder & COO of HDT Bio

Moira Gunn — Wed, 03 Apr 2024 08:00:00 -0700

In this week's episode, Dr. Moira Gunn interviews Dr. Chris Pirie from HDT Bio about their novel approach to cancer prevention through vaccines. They discuss leveraging mRNA technology to target specific tumor mutations and prime the immune system to recognize and eliminate cancer cells. Dr. Pirie highlights ongoing efforts to develop vaccines for prostate, pancreatic, and breast cancers, emphasizing the importance of monitoring immune responses in clinical trials. They also explore the potential for broad-spectrum cancer vaccines and the need to shift towards preventive measures in cancer treatment.

Redefining Acute Myeloid Leukemia (AML) Treatment!!! Dr. Robert Ang, President & CEO of Vor Biopharma

Moira Gunn — Wed, 27 Mar 2024 08:00:00 -0700

This week I speak with Dr. Robert Ang from Vor Biopharma about their innovative approach to treating acute myeloid leukemia (AML). AML is a type of blood cancer that affects the bone marrow, leading to the overgrowth of cancerous cells. Dr. Ang explains that traditional treatments, such as chemotherapy and stem cell transplants, have limitations and risks. Dr. Ang emphasizes the potential of their treatment to revolutionize AML therapy and improve patient outcomes.

Food as Medicine, A Personalized Prescription... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 13 Mar 2024 08:00:00 -0700

Tech Nation Health, Chief Correspondent Dr. Daniel Kraft discusses the concept of "food as medicine." Dr. Kraft emphasizes the evolving understanding of nutrition and its profound impact on health, advocating for a shift towards personalized nutrition using cutting-edge technologies. From continuous glucose monitors to AI-powered apps and sensor toilets, we explore how these innovations enable individuals to measure and optimize their dietary choices.

Repairing Minds, Naturally??? Mark Litton, President & CEO, Athira Pharma

Moira Gunn — Wed, 06 Mar 2024 08:00:00 -0800

Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litton is the President and CEO of Athira Pharma.

Combatting Blood Clots!!! Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics

Moira Gunn — Wed, 28 Feb 2024 08:00:00 -0800

This week, Dr. Daniel Bloomfield from Anthos Therapeutics discusses the prevalence and dangers of blood clots, particularly in patients with cancer. Dr. Bloomfield explains the difference between normal and abnormal blood clotting, the risks associated with blood clots in arteries and veins, and the challenges in balancing clot prevention with the risk of bleeding.

Heartburn, GERD, Cancer??? Dr. Lishan Aklog, CEO of Lucid Diagnostics

Moira Gunn — Wed, 21 Feb 2024 08:00:00 -0800

Dr. Lishan Aklog from Lucid Diagnostics tells us about the path from GERD to, unfortunately, esophageal cancer, and about Lucid’s two-minute diagnostic test which can detect precancerous cells.

From Tummy Tucks to Drug Trials??? Dr. Eric Merle, Chief Business Innovation Officer, GenoSkin

Moira Gunn — Wed, 14 Feb 2024 08:46:00 -0800

Dr. Eric Merle from GenoSkin talks about how they are transforming drug discovery using discarded human skin from surgeries like tummy tucks, revolutionizing the process and accelerating drug development timelines.

XPrize Foundation and $101 Million!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 17 Jan 2024 08:00:00 -0800

Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about the newest XPrize worth an unprecedented $101 Million.

Wound Healing 2.0!!! Dr. Nik Sopko, Chief Scientific Officer at PolarityTE

Moira Gunn — Wed, 10 Jan 2024 08:00:00 -0800

Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers.

Harnessing Natural Killer Cells!!! Dr. Eric Vivier, SVP & CSO of Innate Pharma

Moira Gunn — Wed, 03 Jan 2024 08:00:00 -0800

Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

Can Every Medicine Be a Pill??? Dr. Ray Stevens, CEO of ShouTi Pharma

Moira Gunn — Wed, 27 Dec 2023 08:00:00 -0800

Dr. Ray Stevens, CEO of ShouTi Pharma, talks about their approach in turning IV drugs into pills. Current projects include Diabetes and obesity, and two Pulmonary and Cardiovascular disorders. And these are just their first candidates …

Gut-Brain Connections to Autism, Parkinson's, and More!!! Dr. Stewart Campbell, CEO Axial Therapeutics

Moira Gunn — Wed, 20 Dec 2023 08:00:00 -0800

Dr. Stewart Campbell, CEO of Axial Therapeutics, about their groundbreaking work in Autism–related irritability in teenagers, in Parkinson’s, and in complementing the latest cancer treatments.

Ancient Viruses in our DNA??? Dr. Neil Shubin, Professor & Author University of Chicago

Moira Gunn — Wed, 13 Dec 2023 08:00:00 -0800

On this week’s BioTech Nation University of Chicago professor Dr. Neil Shubin talks about his book “Some Assembly required … Decoding Four Billion Years of Life, from Ancient Fossils to DNA.” Ancient viruses in our DNA? And what about “jumping genes”?

Treating Diseases with Brain Implants??? Nicolas Vachicouras, CEO & Co-Founder Neurosoft Bioelectronics

Moira Gunn — Wed, 06 Dec 2023 08:00:00 -0800

This week we visit the brain, and look at what a flexible brain implant might do – from sensing how your brain is working to actual treatment. Nicolas Vachicouras from Neurosoft Bioelectronics in Geneva, Switzerland talks about the target for their first treatment: severe tinnitus.

The Next Ozempic or Wegovy... But Without the Injection??? Dr. Steffen-Sebastian Bolz, CSO, Aphaia (ah-phi-ah) Pharma

Moira Gunn — Wed, 29 Nov 2023 08:00:00 -0800

Who Could Forget About Dolly The Sheep??? Sir Ian Wilmut, Director, Scottish Centre for Regenerative Medicine

Moira Gunn — Wed, 22 Nov 2023 08:00:00 -0800

We honor Sir Ian Wilmut, the Scottish embryologist who gained worldwide renown as the leader of the scientific research group that cloned the equally famous Dolly. With his recent passing, we air our 2007 BioTech Nation interview, when David Ewing Duncan and I spoke with Dr. Wilmut on the 10th anniversary of Dolly’s birth.

Everybody Has a Thyroid... What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma

Moira Gunn — Wed, 15 Nov 2023 10:19:02 -0800

Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your
parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

It’s All About Cancer, and Covid??? Dr. Andrew Allen, President, CEO, & Co-Founder Gritstone Bio

Moira Gunn — Wed, 08 Nov 2023 08:00:00 -0800

This week on BioTech Nation, Andrew Allen, President, CEO and Co-Founder of Gritstone Bio – a full spectrum look at how cancer starts and cancer treatments have developed … and what next-generation treatment means today with Gritstone’s work in colorectal cancer. And wait for it … the next generation of Covid vaccines.

Is Medical School Curriculum Outdated??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 01 Nov 2023 08:00:00 -0700

Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about how Medical Schools decide what to teach. You might be surprised that it’s based on the Flexner Report … written in … 1910. Is it time for a do-over? And what might that be?

Your Digital Twin May Already Exist!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 25 Oct 2023 08:00:00 -0700

Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about your Digital Twin … your Digital Twin … yes, you have one.

A New Approach To Treating Diabetes... Dr. Anthony Japour, President & CEO, iTolerance

Moira Gunn — Wed, 18 Oct 2023 08:00:00 -0700

Dr. Anthony Japour, President and CEO from iTolerance in Miami, Florida tells us about implanting insulin-producing cells in your pancreas – it’s been tried before, but they have a new approach which just might work.

What's New in Digital Health!!! Dr. Daniel Kraft, Tech Nation Health Chief Correspondent

Moira Gunn — Wed, 11 Oct 2023 08:00:00 -0700

Tech Nation Health Chief Correspondent Dr. Daniel Kraft tells us about the explosion of digital health.

Google's First Radio Interview Ever!!! Larry Page & Sergey Brin, Co-Founders, Google

Moira Gunn — Wed, 04 Oct 2023 08:00:00 -0700

It’s the 25th anniversary of the founding of Google … and 23 years ago, Google founders - Larry Page and Sergey Brin – came to the Tech Nation studios to do their very first radio interview. There’s lots to learn there, including they believed what humans demanded of search, and why they did what they did.

Old Dog, New Tricks ??? ... Dr. Robert Ladner, CEO & Founder, CV6 Therapeutics

Moira Gunn — Wed, 27 Sep 2023 08:00:00 -0700

Dr. Robert Ladner, the Founder of CV6 Therapeutics in Belfast, Northern Ireland, tells us about their work to make a cornerstone cancer chemotherapy, even more effective. First trials are in colorectal and gastrointestinal cancers...

Can Good Viruses Kill Deadly Infections??? Tom Ireland, Science Journalist & Author

Moira Gunn — Wed, 20 Sep 2023 08:00:00 -0700

Science journalist Tom Ireland tells us about a burgeoning field of science, which is changing the fight to successfully treat antibiotic infections. His book is “The Good Virus: The Amazing Story and Forgotten Promise of the Phage”.

Osteoarthritis... Mostly in the Knee, But Pick a Joint!!! Dr. Diem Nguyen, CEO of Xalud Therapeutics

Moira Gunn — Wed, 13 Sep 2023 08:00:00 -0700

Osteoarthritis – mostly in the knee, but pick a joint. Dr. Diem (Zem) Nguyen (N’Win) is the CEO of Xalud (Za-lood) Therapeutics. We’ll talk about their work to reduce the inflammation that drives pain. It’s now in human clinical trials.

Why Do AI One Way, When You Can Do it 25??? Dr. Ben Thomas and Dermot Tierney, CEO & CCO, Amply Discovery

Moira Gunn — Wed, 06 Sep 2023 08:00:00 -0700

Why use one AI approach when you can use 25? CEO Dr. Ben Thomas and Chief Commercial Officer Dermot Tierney from Amply Discovery talks about how their novel approach to AI in drug discovery.

Acute Cannabis Intoxication... Is There An Antidote??? Dr. Ken Cundy, CSO at Anebulo Pharmaceuticals

Moira Gunn — Wed, 30 Aug 2023 08:00:00 -0700

Modern cannabis products, with higher potency than those from the past, can lead to acute cannabis intoxication. Anebulo Pharmaceuticals, led by Chief Scientific Officer Dr. Ken Cundy, is working on an antidote that counteracts the negative effects of THC overdose, potentially benefiting both adults and children.

Gliobastoma + New View on Clinical Trials... Dr. Fahar Merchant, President & CEO Medicenna Therapeutics

Moira Gunn — Wed, 16 Aug 2023 08:00:00 -0700

Glioblastoma is the most aggressive form of brain cancer, and progress in treating Glioblastoma has been elusive. Now, Toronto-based Medicenna has completed a successful Phase 2 with its innovative drug, and is now deep into planning the Phase 3 Trial. Also of interest, the FDA agreed to an unprecedented approach in Phase 2, which not only yields better science, but reduces the cost of the clinical trials themselves. To be sure, this approach will be carried forward into Phase 3. Dr. Fahar Merchant is the President & CEO of Medicenna Therapeutics.

Innovation in Head & Neck Cancers!!! Dr. Mark Newman, CSO, GeoVax

Moira Gunn — Wed, 09 Aug 2023 08:00:00 -0700

In this week's BioTech Nation, we discuss Geovax, a company working on a novel approach to treat head and neck cancers, which are often difficult to treat after standard options have been exhausted. Geovax is developing A2 component therapy, using an enzyme delivered directly to the tumor by a needle injection, followed by an infusion of an inactive form of a chemotherapeutic drug, which becomes toxic to the tumors when processed by the enzyme. The treatment aims to localize the effects, reduce side effects, and potentially activate the immune system to target other tumor cells in the body. Phase two trials are underway, with promising results so far.

We Still Can't Ignore Long Covid... Dr. Jeffrey Cleland, CEO Ashvattha Therapeutics

Moira Gunn — Wed, 02 Aug 2023 08:00:00 -0700

In this week's episode of Biotech Nation, Dr. Jeffrey Cleland, the President and CEO of Ashvattha Therapeutics, discusses their drug development efforts to address long COVID. They discuss the definition of long COVID by the World Health Organization, the prevalence of the condition, and the chronic inflammation that occurs in the body, including the brain. Dr. Cleland explains how their nanomedicine approach aims to selectively target and turn off reactive inflammatory cells, potentially offering a treatment for long haul COVID and other diseases.

Can The Time Needed for CAR-T be shortened? EXUMA Says Yes!!! Dr. Gregory Frost, CEO, EXUMA Biotech

Moira Gunn — Wed, 26 Jul 2023 08:00:00 -0700

In this week's episode of Biotech Nation, Dr. Greg Frost, CEO of Exuma Biotech, discusses their innovative approaches to cancer treatment. They are working on a method to shorten the time and eliminate hospital stays for CAR-T therapy, while also developing a new technology called G-car that combines T cells and NK cells to create a more gentle and effective cancer therapy.

Temporal Lobe Epilepsy - TLE - Will Cell Therapy Work??? Dr. Cory Nicholas, CEO, Neurona Therapeutics

Moira Gunn — Wed, 19 Jul 2023 08:00:00 -0700

A new cell therapy, just entering human clinical trials. It focuses on a particular type of Epilepsy - Temporal Lobe Epilepsy. I speak with Dr. Cory Nicholas, the Co-Founder and CEO of Neurona Therapeutics, about their idea, what they’ve done, and how they plan to approach testing this unprecedented treatment.

New Hope For Glaucoma... Dr. Chris Nave, Managing Director of Brandon Capital and Chair of PolyActiva

Moira Gunn — Wed, 12 Jul 2023 08:00:00 -0700

Join us as Dr. Chris Nave, the managing director of Brandon Capital and Chair of PolyActiva, reveals groundbreaking advancements in eye treatments on this week's episode of Biotech Nation! Discover how their innovative technology is revolutionizing the way we deliver drugs to the eye, offering extended therapy periods and eliminating the need for frequent injections or daily drops. Don't miss out on this eye-opening discussion about the future of ophthalmology and the potential to transform the lives of millions affected by glaucoma and other eye diseases.

The Beauty Contest... Winner Goes to Phase I - Dr. Richard Austin, Founder & CEO Reglagene

Moira Gunn — Wed, 05 Jul 2023 08:00:00 -0700

Join Dr. Richard Austin, Founder and CEO of Reglagene, as he reveals the intense process of selecting the most promising drug candidate for treating brain cancer. Delve into the intriguing world of the "Bake Off" or "beauty contest" where molecules compete to be the breakthrough therapy in human clinical trials. Discover the challenges of penetrating the blood-brain barrier and the quest to revolutionize brain cancer treatment.

Sticky Proteins??? Alzheimer's, Parkinson's, and ALS...Dr. Maria Maccecchini, President & CEO, Annovis Bio

Moira Gunn — Wed, 28 Jun 2023 08:00:00 -0700

This week we explore the commonalities among neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS. Dr. Maria Macccecchini, Founder and CEO of Annovis Bio, discusses the role of sticky proteins in these diseases and how her company is developing a drug to prevent the aggregation of these proteins. The episode also touches on their ongoing clinical trials for Alzheimer's and Parkinson's and their potential application in treating traumatic brain injuries.

When Your Distant Cousins ID You For Murder… Ed Humes, Author of "The Forever Witness"

Moira Gunn — Wed, 21 Jun 2023 08:00:00 -0700

Moira speaks with Pulitzer Prize-winning author, Ed Humes. His latest is “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA, and while it reads like a fast-paced Cold Case on steroids – it provides details no fiction writer would dare to make up, like the unexpected involvement of the famous true crimes writer, Ann Rule, and a person whose DNA skills are familiar to fans of the PBS documentary series, “Finding your roots with Henry Louis Gates, Jr.”

Are Fibroblasts All Over My Body??? Dr. Hamid Khoja, CSO at FibroBiologics

Moira Gunn — Wed, 14 Jun 2023 08:00:00 -0700

Dr. Hamid Khoja, Chief Scientific Officer of Fibro Biologics, discusses the potential of fibroblasts in regenerative medicine, highlighting their abundance and diverse functions in the body. He shares insights from their ongoing human clinical trials, including the use of fibroblasts for treating degenerative disc disease and multiple sclerosis. Dr. Khoja also mentions their promising findings in animal studies related to diabetic foot ulcers.

Engineering Viruses to Treat Solid Tumors... Dr. Paul Peter Tak, CEO of Candel Therapeutics

Moira Gunn — Tue, 06 Jun 2023 08:00:00 -0700

Dr. Paul Peter Tack, CEO of Candel Therapeutics, unveils their groundbreaking approach to cancer treatments using engineered viruses. Discover how these viruses are harnessed to target solid tumors, deliver therapeutic genes, and activate the patient's immune system for a powerful anti-cancer response.

AI Three Different Ways to a New Drug??? Dr. Francois Vigneault, Co-Founder & CEO Shape Therapeutics

Moira Gunn — Wed, 31 May 2023 08:00:00 -0700

Discover the limitless potential of mRNA engineering as Dr. Francois Vigneault, Co-Founder and CEO of Shape Therapeutics, discusses their groundbreaking work in using mRNA to address genetic mutations in diseases like Parkinson's and Alzheimer's, offering hope for effective treatments and prevention strategies. Join us as we delve into the world of mRNA technology and its transformative impact on healthcare.

Fighting the Most Advanced Prostate Cancer... Dr. Philip Kantoff, CEO Convergent Therapeutics

Moira Gunn — Wed, 24 May 2023 08:00:00 -0700

200,000 men at diagnosed each year with Prostate cancer … beginning a journey of many successive treatments. Still, 35,000 men die as a result of prostate cancer. Convergent Therapeutics is focusing on the most advanced, intractable cases of prostate cancer. We speak with, Dr. Philip Kantoff is its Co-Founder, Chief Medical Officer and CEO.

A Different Approach, A New Cancer Drug... Dr. Paul Lammers, CEO Triumvira Immunologics

Moira Gunn — Wed, 17 May 2023 08:00:00 -0700

Cancer treatments which work with the immune system are making great strides, with Keytruda from Merck being perhaps the best known. Still there is much work to be done – both in developing unprecedented new treatments, as well as treatments which might combine with our existing treatments to make them even more effective. Triumvera (try-um-VEERA) Immunologics is working on both. Dr. Paul Lammers is its CEO.

Are Your Genes Failing You??? Dr. Noah Davidsohn, Co-Founder & CSO Rejuvenate Bio

Moira Gunn — Wed, 10 May 2023 08:00:00 -0700

Dr. Nolan Davidson, the Co-Founder and Chief Scientific Officer of Rejuvenate Bio, discusses the importance of regulating protein expression and the role it plays in aging. He talks about the three primary genes that drive health and the need to maintain their ideal levels to avoid diseases such as heart disease, liver disease, or kidney disease.

25 Years in the Making - Treatment in Schleroderma? Dr. Darren Kelly, CEO, Certa Therapeutics

Moira Gunn — Wed, 19 Apr 2023 07:00:00 -0700

Dr. Darren Kelly, a professor and researcher at the University of Melbourne and the Founder and CEO of Certa Therapeutics, tells us about their clinical trials addressing the skin condition: schleroderma. Their unprecedented approach and the results of their latest trial are worth noting.

Fatty Liver, NASH, Cirrhosis - Can They Be Stopped??? Dr. Robert Foster, CEO Hepion Pharmaceuticals

Moira Gunn — Wed, 12 Apr 2023 07:00:00 -0700

Did you know that 1 in 4 Americans suffer from fatty liver disease? And that can lead to a more serious condition called Nash, which can ultimately cause cirrhosis of the liver. Hepion Pharmaceuticals is currently in clinical trials to successfully treat Nash. Learn more about how to take care of your liver on today's episode of BioTech Nation with Dr. Robert Foster, CEO of Hepion Pharmaceuticals.

Hand Foot Skin Reaction - A Painful Chemotherapy Side Effect - Could There Be a Treatment?? Dr. Mike McCullar, CEO of OnQuality Pharmaceuticals

Moira Gunn — Wed, 22 Mar 2023 08:00:00 -0700

A side effect of chemotherapy, where hands and feet may be raw, painful, and immobilized. With no current treatment, a new candidate has just finished Phase II clinical trials. We’ll hear from Dr. Michael McCullar, the CEO of OnQuality Pharmaceuticals.

Has Medtech Excluded Persons of Color & Women?? Dr. Patrice Matchaba President, Novartis US Foundation

Moira Gunn — Wed, 08 Mar 2023 16:55:49 -0800

Dr. Patrice Matchaba, the President of the Novartis US Foundation, shows us how medical technology can create systemic racism, both in the medical field and in human clinical trials.

Safe NON-OPIOID Pain Relief - Is It Possible? Dr. Hernan Bazan, Co-Fdr & CEO, South Rampart Pharma

Moira Gunn — Wed, 01 Mar 2023 16:25:30 -0800

The next generation of pain relief – non-opioid pain relief - with the goal of being equally powerful pain relief without addiction. Dr Hernan Bazan is the Co-Founder & CEO of South Rampart Pharma in New Orleans.

Long Covid related to Fibromyalgia? Dr. Seth Lederman, Tonix Pharmaceuticals

Moira Gunn — Wed, 22 Feb 2023 16:47:39 -0800

Dr. Seth Lederman, Co-Founder and CEO of Tonix Pharmaceuticals, tells us that Long Covid may be related to Fibromyalgia. Now recruiting in advanced Human Clinical Trials ... www.tonixpharma.com

The Oxford Dodo? ... Joe Hernandez, Blue Water Vaccines

Moira Gunn — Wed, 15 Feb 2023 09:24:14 -0800

Even Saturday Night Live couldn’t resist the story of a “genetics engineering company” trying to de-extinct the dodo bird. Blue Water Vaccines, founder and CEO Joe Hernandez tells us about his early quest to develop a universal flu vaccine, bringing him face-to-face – so to speak – with the Oxford Dodo. And of course, he funds decoding its DNA.

Getting Immune Systems to Recognize HER2+ tumors - Dr. Randy Schatzman, President & CEO, Bolt Biotherapeutics

Moira Gunn — Thu, 09 Feb 2023 11:27:45 -0800

Bolt Biotherapeutics’ Dr. Randy Schatzman talks about the role of myeloid cells in teaching our immune systems to recognize tumors in our own bodies and then eliminate them. Nearly two dozen forms of HER2-related cancers are being studied. (16 mins)

22-45 Getting a Vaccination? What about a nasal spray?

Moira Gunn — Wed, 01 Feb 2023 17:05:27 -0800

Dr. Robert Coleman, the Co-Founder and CEO of Codagenix, shows us how to precisely engineer viruses to be effective vaccines, which can be delivered nasally – you heard that right – no needle.

23-03 Dr. Rob Ross, CEO, Surface Oncology

Moira Gunn — Sun, 15 Jan 2023 07:12:42 -0800

Surface Oncology's strategy to improve on the first generation of immuno-oncology drugs. Their Phase 2 trials in lung cancer and liver cancer are underway and recruiting.

23-01 Gene Kinney, President & CEO, Prothena Biosciences

Moira Gunn — Sat, 07 Jan 2023 09:51:01 -0800

Prothena's 1-2-3 punch for Alzheimer’s + their work in Parkinson’s, ALS, and the role of Amyloids in Down Syndrome

22-52 Edward Humes, Pulitzer Prize Winner, "The Forever Witness"

Moira Gunn — Tue, 27 Dec 2022 18:51:59 -0800

In a long-form feature from Tech Nation, it’s Pulitzer Prize-winning author, Edward Humes, with “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA from a forensic investigation standpoint, and while it reads like a fast-paced Cold Case on steroids – it provides details no fiction writer would dare to make up, including the unexpected involvement of the famous true crimes writer, Ann Rule, and a person whose DNA skills are familiar to fans of the PBS documentary series, “Finding Your Roots with Henry Louis Gates, Jr.”

22-51 Keven Ali, CEO, Organon

Moira Gunn — Sat, 17 Dec 2022 01:00:00 -0800

A new global company with 64 products, many of which are for women? Kevin Ali is the CEO of Organon.

22-50 Dr. Steve Worland, Co-Founder & CEO, eFFECTOR Therapeutics

Moira Gunn — Wed, 14 Dec 2022 01:00:00 -0800

Cancer is a hijacker, hijacking cells for its own purposes. And that’s where eFFECTOR Therapeutics is determined to intervene. Dr. Steve Worland, the Co-Founder & CEO, talks about just two of the candidates in its pipeline: One is for Non-small cell lung cancer and another for ER+ breast cancer, with these and other clinical trials enrolling now.

22-49 Dr. Zandy Forbes, Pres & CEO, MeiraGTx

Moira Gunn — Sat, 10 Dec 2022 01:00:00 -0800

Like the idea of replacing some of your DNA with DNA that works better? And what if you want that new DNA to stop? Dr. Alexandria Forbes, the President & CEO of MeiraGTx, tells us about their work in retinitis pigmentosa and Parkinson’s – two of many clinical trials enrolling right now.

22-48 Dr. Robert Ang, President & CEO, Vor Biopharma

Moira Gunn — Wed, 07 Dec 2022 01:00:00 -0800

Vor Biopharma has a unique approach to a particular kind of cancer – Acute Myeloid Leukemia – perhaps better known to you, as AML. Dr. Robert Ang is Vor's President & CEO.

22-47 Dr. James Mackay, President & CEO, Aristea Therapeutics

Moira Gunn — Sun, 04 Dec 2022 01:00:00 -0800

Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's called PPP, or Palmoplantar Pustulosis. Dr. James Mackay is the President & CEO of Aristea Therapeutics.

22-46 Dr. Maria Maccecchini, Founder, President & CEO, Annovis Bio

Moira Gunn — Wed, 30 Nov 2022 01:00:00 -0800

Alzheimer’s, Parkinson’s and ALS, among others, are often grouped as Neurodegenerative Disorders. While they each present a different profile of symptoms, what do they have in common? Dr. Maria Maccecchini, the Founder, President & CEO of Annovis Bio, says, "Sticky proteins".

22-16 Triple-Negative Breast Cancer is the most aggressive of all

Moira Gunn — Sun, 27 Nov 2022 10:44:14 -0800

Anixa is pioneering a new approach to preventing the truly aggressive triple-negative form of breast cancer. Based on research from Cleveland Clinic, this approach has the potential to treat other breast cancers as well as ovarian cancer. Dr. Amit Kumar is the President & CEO. More information is available at anixa.com.

Dr. George Yancopoulos, CEO, Regeneron

Moira Gunn — Tue, 14 Jun 2022 08:01:34 -0700

Dr. George Yancopoulosis is the President and Chief Scientific Officer of Regeneron. Regeneron is successful on many levels but is perhaps best known for its Covid treatment, directly infusing antibodies. This, of course, requires innovative science … but how do get students to become scientists? Dr. Yancopoulos has an answer.

Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics

Moira Gunn — Mon, 13 Jun 2022 11:50:48 -0700

Blood clots of any sort are dangerous. So dangerous in fact, that 1 in 4 people die from blood clots - independent of medical condition, medicines they take, or medical procedures they undergo. Dr. Daniel Bloomfield, the Chief Medical Officer of Anthos Therapeutics, describes their approach to preventing bleeding while avoiding blood clotting.

Mark Litton, President & CEO, Athira Pharma

Moira Gunn — Thu, 09 Jun 2022 15:01:54 -0700